MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

Media coverage

• Title	MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
  Media name/outlet	BioSpace
  Country/Territory	United States
  Date	9/01/25
  URL	https://www.biospace.com/press-releases/moonlake-initiates-three-new-clinical-trials-and-further-expands-the-portfolio-of-indications-for-the-nanobody-sonelokimab
  Persons	Mark Lebwohl